These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26071430)

  • 61. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
    Liu F; Walters SJ; Julious SA
    BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
    Yada S; Hamada C
    Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase II trial designs in the presence of stratification.
    Tan SB; Machin D
    Stat Med; 2006 Sep; 25(18):3220-2; author reply 3222-3. PubMed ID: 16906490
    [No Abstract]   [Full Text] [Related]  

  • 68. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
    Mayo MS; Gajewski BJ
    Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines.
    Cunanan KM; Koopmeiners JS
    Stat Med; 2017 Jan; 36(1):43-53. PubMed ID: 27545299
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Single-arm phase IIA clinical trials with go/no-go decisions.
    Zhong B
    Contemp Clin Trials; 2012 Nov; 33(6):1272-9. PubMed ID: 22796490
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Using historical control information for the design and analysis of clinical trials with overdispersed count data.
    Gsteiger S; Neuenschwander B; Mercier F; Schmidli H
    Stat Med; 2013 Sep; 32(21):3609-22. PubMed ID: 23722585
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Optimal adaptive two-stage designs for phase II cancer clinical trials.
    Englert S; Kieser M
    Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sample sizes for phase II clinical trials derived from Bayesian decision theory.
    Brunier HC; Whitehead J
    Stat Med; 1994 Dec 15-30; 13(23-24):2493-502. PubMed ID: 7701149
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The importance of piloting an RCT intervention.
    Feeley N; Cossette S; Côté J; Héon M; Stremler R; Martorella G; Purden M
    Can J Nurs Res; 2009 Jun; 41(2):85-99. PubMed ID: 19650515
    [TBL] [Abstract][Full Text] [Related]  

  • 76. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project.
    Meurer WJ; Lewis RJ; Tagle D; Fetters MD; Legocki L; Berry S; Connor J; Durkalski V; Elm J; Zhao W; Frederiksen S; Silbergleit R; Palesch Y; Berry DA; Barsan WG
    Ann Emerg Med; 2012 Oct; 60(4):451-7. PubMed ID: 22424650
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A framework for prospectively defining progression rules for internal pilot studies monitoring recruitment.
    Hampson LV; Williamson PR; Wilby MJ; Jaki T
    Stat Methods Med Res; 2018 Dec; 27(12):3612-3627. PubMed ID: 28589752
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A hypothesis test of feasibility for external pilot trials assessing recruitment, follow-up, and adherence rates.
    Wilson DT; Brown J; Farrin AJ; Walwyn REA
    Stat Med; 2021 Sep; 40(21):4714-4731. PubMed ID: 34121221
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sample size calculation in randomised phase II selection trials using a margin of practical equivalence.
    Dehbi HM; Hackshaw A
    Trials; 2020 Mar; 21(1):301. PubMed ID: 32228674
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimal designs for phase II/III drug development programs including methods for discounting of phase II results.
    Erdmann S; Kirchner M; Götte H; Kieser M
    BMC Med Res Methodol; 2020 Oct; 20(1):253. PubMed ID: 33036572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.